Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People Round-Up: Bhadauria Named As Amneal CSO

Executive Summary

Amneal gets a new CSO, Acino restructures its board under a new chair, the AAM adds an assistant general counsel and the British Biosimilars Association names a vice-chair, as well as other people movements from around the generics, biosimilars and value-added medicines industries.

You may also be interested in...



If Amneal Goes Global Again, It Intends To Go Big

Having just sold off relatively small operations in the UK and Germany, Amneal would look for large-scale deals if it were to expand again beyond its US powerbase. The US generics and specialty brands company is also looking to expand its injectables business and is considering a move into biosimilar insulins.

IGBA Joins Fight The Fakes Alliance

As the Fight The Fakes Alliance holds its fifth annual “Fight The Fakes Week,” the IGBA has signed to become a new member of the association as it calls for fresh action to prevent falsified medicines from reaching patients.

Neuraxpharm Expands European Reach With Dutch Operation

Neuraxpharm has made its latest move into a new European market, this time opening up a new unit in the Netherlands that will be led by the firm’s German head Philipp Pohoralek as country manager.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB140264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel